Why Recursion Pharmaceuticals is on investors’ radar today

Recursion Pharmaceuticals (RXRX) has attracted attention after recent trading, with the share price at $3.07 and returns showing mixed performance over the past week, month and past 3 months.

For investors tracking high risk biotech names, the company’s clinical stage drug discovery pipeline, revenue of $74.681 million, and market cap of about $1.5b provide context for assessing whether the current level looks appealing or expensive.

The latest 8.1% 1 day share price return at US$3.07 comes after weaker momentum, with a 30 day share price return of 16.35% and a year to date share price return of 26.9%, alongside a 1 year total shareholder return of 39.74% and a 3 year total shareholder return of 53.27%. This points to fading momentum despite the bounce.

If you are weighing RXRX against other high risk biotech ideas, it can help to see how peers are trading through a dedicated screen of 34 healthcare AI stocks

With Recursion trading at US$3.07, an intrinsic discount of about 68% and a price target gap that is very large, the key question is whether the stock is cheap today or whether the market already reflects future growth.

Most Popular Narrative: 55.8% Overvalued

Against the last close at $3.07, the most followed narrative pegs Recursion’s fair value at $1.97, presenting a clear gap for investors to assess.

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said

This narrative leans heavily on insider activity, past share price swings and bold expectations about the drug pipeline. It raises questions about which revenue, margin and valuation assumptions sit underneath that $1.97 fair value and 7.13% discount rate, and how those inputs align with forecasts that still leave RXRX unprofitable. The full story connects these pieces in a way the share price alone cannot.

Result: Fair Value of $1.97 (OVERVALUED)

However, there are clear risks to this bearish view, including the 41.64% annual revenue growth and the active clinical pipeline, either of which could shift sentiment quickly.

Another view on RXRX's value

While the user narrative tags RXRX as 55.8% overvalued at a fair value of $1.97, the SWS DCF model points the other way, with a future cash flow value of $9.54 and the current $3.07 price described as trading below that level. When two methods disagree this much, which one do you treat as your anchor?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between risk and reward, this is the moment to check the numbers yourself and decide where you stand. Start by weighing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If RXRX has your attention, do not stop here, use the screener to line up a few more ideas that genuinely fit your portfolio goals.

• Target income first and scan a focused list of companies offering reliable cash returns through 12 dividend fortresses.
• Hunt for quality at a sensible price by checking stocks that score well on valuation and fundamentals with the 58 high quality undervalued stocks.
• Prioritize resilience and sleep a little easier by reviewing companies that carry lower risk profiles inside the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.